CD58 loss in tumor cells confers functional impairment of CAR T cells

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treating a variety of hematologic malignancies, but resistance to this treatment in some patients limited its wider application. Using an unbiased genome-wide clustered regularly interspaced short palindromic repeats...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xin, Chen, Deyun, Ma, Xinran, Wang, Yao, Guo, Yelei, Wei, Jianshu, Tong, Chuan, Zhu, Qi, Lu, Yuting, Yu, Yang, Wu, Zhiqiang, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649996/
https://www.ncbi.nlm.nih.gov/pubmed/35728062
http://dx.doi.org/10.1182/bloodadvances.2022007891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649996/
https://www.ncbi.nlm.nih.gov/pubmed/35728062
http://dx.doi.org/10.1182/bloodadvances.2022007891

Ejemplares similares